Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 50 entries
View as:

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04117945 Org: User:
Start: 03/03/20 End: 03/31/25 Due: 03/31/26

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Phase: N/A Priority: Normal
NCT ID: NCT02585713 Org: User:
Start: 11/20/15 End: 12/24/19 Due: 12/24/20

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04351230 Org: User:
Start: 11/11/20 End: 02/16/22 Due: 02/16/23

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase: N/A Priority: Normal
NCT ID: NCT05356897 Org: User:
Start: 10/31/23 End: 09/17/24 Due: 09/17/25

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06238648 Org: User:
Start: 01/31/24 End: 12/31/30 Due: 12/31/31

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04088188 Org: User:
Start: 01/25/21 End: 12/01/23 Due: 12/01/24

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04756401 Org: User:
Start: 12/08/22 End: 12/30/27 Due: 12/30/28

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03992456 Org: User:
Start: 04/24/20 End: 10/07/24 Due: 10/07/25

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Phase: N/A Priority: Normal
NCT ID: NCT01532089 Org: User:
Start: 03/16/12 End: 08/18/20 Due: 08/18/21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02158520 Org: User:
Start: 10/18/13 End: 10/30/19 Due: 10/30/20

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Phase: N/A Priority: Normal
NCT ID: NCT04197687 Org: User:
Start: 02/20/20 End: 01/15/25 Due: 01/15/26

Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02234180 Org: User:
Start: 09/30/14 End: 06/08/16 Due: 06/08/17

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT05246670 Org: User:
Start: 05/16/22 End: 02/28/25 Due: 02/28/26

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Phase: N/A Priority: Normal
NCT ID: NCT01867294 Org: User:
Start: 08/31/12 End: 06/13/14 Due: 06/13/15

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05168163 Org: User:
Start: 05/27/22 End: 12/31/26 Due: 12/31/27

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02628405 Org: User:
Start: 05/20/16 End: 12/20/25 Due: 12/20/26

Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02949219 Org: User:
Start: 03/24/17 End: 12/31/24 Due: 12/31/25

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03981614 Org: User:
Start: 10/29/19 End: 07/02/24 Due: 07/02/25

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04390243 Org: User:
Start: 11/16/20 End: 11/01/23 Due: 11/01/24

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02292758 Org: User:
Start: 12/12/14 End: 09/27/19 Due: 09/27/20

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Phase: N/A Priority: Normal
NCT ID: NCT04042831 Org: User:
Start: 06/24/20 End: 03/30/25 Due: 03/30/26

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04626791 Org: User:
Start: 08/03/21 End: 08/03/28 Due: 08/03/29

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02758717 Org: User:
Start: 05/13/16 End: 09/13/24 Due: 09/13/25

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02640053 Org: User:
Start: 12/23/15 End: 10/05/18 Due: 10/05/19

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03337087 Org: User:
Start: 11/02/18 End: 08/09/25 Due: 08/09/26